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Joanna Owoc-Lempach,1 Marek Ussowicz,1 Agnieszka Dyla,1 Jakub Musiał,1
Dominika Paz´dzior,1 Dominik Turkiewicz,1,2 Alicja Chybicka1The aim of our study was to compare the results of unrelated donor (UD) peripheral blood stem cell trans-
plantation versus UD bone marrow transplantation and to analyze the impact of infused CD341 and CD31
cell doses on survival and incidence of severe graft-versus-host disease (GVHD) in 187 children who under-
went UD hematopoietic cell transplantation with the use of in vivo T cell depletion (antithymocyte globulin or
CAMPATH-1H). HLA typing was performed at the ‘‘high-resolution’’ level. Patients receiving $10  106
CD341 cells/kg and$4 108 CD31 cells/kg had better overall and disease-free survival. Multivariate analysis
has shown that both infused CD341 cell dose\10 106/kg and CD31 cell dose\4 108/kg were indepen-
dent risk factors for mortality (relative risk [RR] 1.8 and 1.71, P 5 .009 and .016, respectively). Regarding
disease-free survival, multivariate analysis has revealed another independent risk factor for poor outcome
apart from the 2 earlier-mentioned cell doses, which was the use of donors mismatched at 2 HLA antigens
or 3 HLA allele/antigens (RR 2.5, P5.004). In age groups 0-10 years and 10-20 years, CD341 cell doses higher
than the age-adjusted median dose clearly favored survival. Higher infused doses of CD341 and CD31 cells
did not result in an increased rate of severe GVHD. The use of mismatched donors was the only independent
risk factor for the incidence of severe acute GVHD (RR 2.2, P5.046). The report demonstrates for the first
time in a pediatric cohort, that higher doses of transplanted CD341 and CD31 cells lead to an improved sur-
vival without an increased riskof severe GVHD. The study findings may be limited to the population of patients
receiving in vivo T cell depletion, which is now broadly used in unrelated donor setting in Europe.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) has become a standard therapy for children
with a variety of both malignant and nonmalignant
diseases [1]. In Poland, only approximately 20% of
children have an HLA matched sibling donor (MSD)
available. The remaining 80% of patients have to be
transplanted from alternative donors. For children
with rare HLA haplotypes, it remains extremely
difficult and time consuming to find a fully matched
unrelated donor (MUD). It is generally acceptable to
use unrelated donors (UD)mismatched at 1HLA allele
or antigen. Such UDs are categorized as MUD, to-
gether with fully matched ones (10/10-allele matched).
Table 1. Primary Diagnosis (n 5 187 Patients)
Malignant N Nonmalignant N
ALL 67 SAA 13
AML 33 Fanconi Anemia 5
CML 25 X-ALD 4
MDS 18 SCID 3
NHL 5 WAS 2
JMML 4 Omenn Syndrome 2
HD 2 X-CGD 2
Biol Blood Marrow Transplant 16:1388-1401, 2010 1389Effect of CD341 or CD31 Dose on Pediatric UD-HSCTAccording to the acute lymphoblastic leukemia (ALL)
international BFM SCT 2008 (Vienna, Austria) trans-
plant protocol,UDHSCT fromdonorsmismatched at
more than 1 HLA antigen or allele, requires extensive
in vitro T cell depletion. There are, however, two pub-
lished studies confirming low mortality of children
undergoing HSCT from 7 to 8/10 HLA allele-
matched UD with the use of antithymocyte globulin
(ATG), but not T cell depletion in vitro [2,3].
There is an unresolved question whether
unmanipulated UD-peripheral blood stem cell
transplantation (PBSCT) leads to a worse overall out-
come, and a higher incidence of severe graft-versus-
host disease (GVHD) in both adults and children, in
comparison with well-established UD bone marrow
transplantation (BMT). It is well known that PBSC
grafts contain approximately 1 log more mature T
cells, which may result in a higher rate of severe (often
fatal) acute or/and chronic GVHD (aGVHD,
cGVHD) posttransplant.
The aim of our study was to compare the results of
UD PBSCT versus UD BMT and analyze the impact
of CD341 and CD31 cell doses in the grafts in a large
pediatric patient population. PBSC grafts with larger
amounts of CD341 and CD31 cells may lead to
a prompter engraftment and improved outcome be-
cause of a more pronounced graft-versus-malignancy
effect [4,5]. However, studies on both adults and
children show discrepant results with regard to
overall survival (OS) and occurrence of aGVHD and
cGVHD after UD PBSCT [6-12]. Based on the fact
that the majority of volunteer donors in Germany
and Poland prefer (sometimes exclusively) PBSC
donation, the number of UD PBSCT in our center
has increased steadily over the last decade. To our
knowledge, there is no published study with a higher
number of UD PBSCTs performed in children and
adolescents. Furthermore, data on the impact of
CD341 and CD31 cell doses in the UD graft on the
OS and disease-free survival (DFS) and aGVHD/
cGVHD is scarce for adults [13-17] and virtually
nonexistent for children. In this multivariate detailed
analysis of different factors influencing the outcome
and the incidence of severe GVHD post-UD HSCT,
we demonstrate for the first time in a large pediatric
cohort, that higher doses of transplanted CD341 and
CD31 cells lead to improved survival without an
increased risk of severe GVHD, provided that in vivo
T cell depletion is used.LCAL 1 Griscelli Syndrome 1
Total 155 Total 32
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronicmyelogenous leukemia;MDS,myelodysplastic syn-
drome; NHL, non-Hodgkin lymphoma; JMML, juvenile myelomonocytic
leukemia; HD, Hodgkin disease; LCAL, large cell anaplastic lymphoma;
SAA, severe aplastic anemia; X-ALD, X-linked adrenoleukodystrophy;
SCID, severe combined immunodeficiency disease; WAS, Wiskott-
Aldrich syndrome; X-CGD, X-linked chronic granulomatous disease.MATERIALS AND METHODS
Patients
Between the years 2000 and 2008, 187 children and
adolescents (112 males and 75 females) with malignant
(n 5 155) and nonmalignant disorders (n 5 32)underwent unmanipulated allogeneic UD HSCT at
our center (Table 1). Their median age at transplant
was 9.6 years (range: 0.6-20.2 years). All patients with
malignant disorders were given disease-specific mye-
loablative (MA) conditioning regimens according to
Europeanprotocols, except for those receiving a second
transplant, who were grafted with disease-adapted re-
duced-toxicity regimens including treosulfan (instead
of busulfan). Total body irradiation (TBI) was used in
51 patients. Patients with nonmalignant disorders
were conditioned according to the guidelines of the
European Blood and Marrow Transplant (EBMT) In-
born ErrorsWorking Party except for patients with se-
vere aplastic anemia (SAA) conditioned mostly with
treosulfan and cyclophosphamide. For GVHD pro-
phylaxis, rabbit ATG (Fresenius, median dose 30 mg/
kg) was used in 160 patients, whereas 22 children
received Thymoglobuline (Genzyme, median dose 10
mg/kg) and 5 other patients Campath-1H (median
dose 1 mg/kg). Standard Cyclosporine A (CsA) and
short methotrexate (MTX) were added toGVHD pro-
phylaxis. The risk status of the patients at transplant
was assessed by our own modification of the classifica-
tion proposed by Meisel et al. [12]: patients with acute
lymphoblastic leukemia (ALL)/acute myelogenous
leukemia (AML) in first and second complete remission
(CR), chronic myelogenous leukemia (CML) in the
first chronic phase, myelodysplastic syndrome
(MDS)-refractory cytopenia, non-Hodgkin lymphoma
(NHL) inCR, and any nonmalignant disease were con-
sidered standard risk (n 5 118), whereas children with
ALL/AML in equal to or greater than the third CR
or nonremission, CML equal to or greater than the
accelerated phase, MDS-refractory anemia with excess
of blasts, juvenile myelomonocytic leukemia (JMML),
NHL in nonremission, and patients undergoing any
second transplant were classified as high risk (n 5 69).
The grafted cells were obtained from HLA-allele
matched or mismatchedUDs (age 19-56 years, median
1390 Biol Blood Marrow Transplant 16:1388-1401, 2010K. Kałwak et al.34 years). HLA typing was performed at the high-
resolution level (4 digits) in A),B), Cw), DRB1), and
DQB1) alleles. There were 159 matched- and 28
mismatched donor-recipient pairs, respectively (ac-
cording to ALL international BFM SCT 2008 criteria,
all 10 alleles were high-resolution typed). Table 2 pres-
ents the detailed distribution of different combinations
of HLA-mismatched donor-recipient pairs. Table 3
provides details on the patient sex, age, diagnosis, risk
status at transplant, donor age, donor/recipient
CMV-status and blood group compatibility, year of
transplant (2000-2004 versus 2005-2008), TBI use,
degree of HLA-match and data on neutrophil and
platelet recovery within the 3 groups divided according
to stem cell source (peripheral blood [PB] versus BM),
and number of infused CD341 and CD31 cells in the
graft. Median number of transplanted CD341 cells
was 11.3 106/kg (range: 0.8-57.8) in the PBSC group
and 3.4  106/kg (range: 0.8-11.0) in the BM group
(P\ .001).Median number of transplantedCD31 cells
was 5.2  108/kg (range: 0.2-20.0) in the PBSC group
and 0.4  108/kg (range: 0.04-10.1) in the BM group
(P\ .001).
The study was approved by the local Ethics Com-
mittee, and patients over 18 years old or parents of
patients under 18 years signed informed consents.
Aims of the Study
As the endpoints of this prospective study, hemato-
logic recovery, OS, DFS, the incidence of severe acuteTable 2. Types of HLA-Mismatched Donor-Recipient Pairs
Full allele match (10/10) –
A)B)Cw)DRB1)DQB1) 94/187 (50,26%)
One antigen or allele mismatch (9/10) 65 (47+18) /187 (34,76%)
A)-mismatch 14 (9+5)
B)-mismatch 8 (2+6)
Cw)-mismatch 33 (30+3)
DRB1 )-mismatch 2 (0+2)
DQB1)-mismatch 8 (6+2)
Two allele/antigen mismatch (8/10) 23/187 (12.29%)
Two antigen mismatch (8 ant)
B)+Cw) 3
A)+Cw) 3
Cw)+Cw) 1
Two allele or two antigen + allele mismatch
B)+Cw) 6
C)+DQB1) 3
B)+DQB1) 2 (1+1)
A)+B) 2 (1+1)
Cw)+Cw) 1
A)+Cw) 1
A)+A) 1
Three allele/antigen mismatch (7/10) 5/187 (2.67%)
B)+Cw)+Cw) 1
B)+Cw)+Cw) 1
A)+B)+Cw) 1
B)+B)+DQB1) 1
B)+B)+Cw) 1
8 ant indicates abbreviation for the group of two HLA antigen-
mismatched recipient pairs; antigen mismatches are depicted as first
number in brackets.GVHD (aGVHD grade III-IV) and extensive chronic
GVHD (cGVHD) were compared within 3 study co-
horts of patients:
1. Recipients of PBSC versus BM;
2. Patients grafted with higher CD341 cell dose ($10
 106/kg) versus those grafted with lower dose
(\10  106/kg).
3. Patients grafted with higher CD31 cell dose ($4 
108/kg) versus those grafted with lower dose
(\4  108/kg).
The cell dose cutoffs were chosen by taking 2
approximately similar (in numbers) cohorts of chil-
dren. The cell dose of 10  106 CD34/kg was slightly
higher than median (9.72  106 CD34/kg), so we
rounded the division value up to 10  106. Similarly,
the cell dose of 4  108 CD3/kg was slightly lower
than themedian (4.26 108/kg), so we rounded the di-
vision value down to 4  108/kg. We concluded that
values close to medians were good cutoff points for
cell doses (as in NMDP study) [17].
To avoid a possible bias in favor of higher CD341
cell doses in younger patients, we analyzed separately
the age groups 0-10 years and 10-20 years and then
0-5 years, 5-10 years, 10-15 years, and older. We
looked at the influence of CD341 or CD31 cell dose
(above and below age-adjusted medians) on OS, DFS,
and both severe aGVHD or extensive cGVHD in
relatively homogenous smaller age groups. Ten years
was chosen to be the age cutoff because it was close to
the median (9.6 years), so we rounded up the cutoff
value to 10.
In addition, a parallel subanalysis of patients
grafted with different CD341 and/or CD31 cell doses
was performed using a method (analysis of quartiles)
similar to the one described in a recently published
NMDP study [16].
Furthermore, the secondary aim of our study was
to analyze the impact of HLA mismatch on the out-
comes.
Hematologic recovery was defined as the achieve-
ment of an absolute neutrophil count (ANC) .0.5
 109/L and/or platelet count.50  109/L for 3 con-
secutive days, respectively. For the analysis of cGVHD,
only patients surviving beyond day 1100 were taken
into consideration. GVHD was assessed according to
well-known clinical symptoms, laboratory tests, and
histopathology, as applicable. aGVHD and cGVHD
were graded according to the criteria described
previously and adapted for children [18,19]. aGVHD
was treated mostly with methylprednisolone and CsA.
In case of steroid resistance nonstandardized fashion
including ATG, etanercept, or mycophenolate mofetil
(MMF) or a combination of 3-4 immunosuppressive
drugs was used. Extensive cGVHD was treated
with methylprednisolone, CsA, etanercept, and/or
MMF.
Table 3. Characteristics of the Study Cohorts: Univariate Analysis of Multiple Variables
Stem Cell Source CD34+ Cell Dose CD3+ Cell Dose
PB BM
Variables N (%) N (%) P* N Median (SE) P† N Median (SE) P†
Recipient sex .680 .487 .535
male 88 (60.7) 24 (57.1) 75 9.42 (0.86) 73 4.33 (0.35)
female 57 (39.3) 18 (42.9) 112 9.78 (1.27) 110 4.11 (0.48)
Recipient age .256 .000 .000
$10 years 65 (44.8) 23 (54.8) 89 7.20 (0.56) 86 3.07 (0.27)
<10 years 80 (55.2) 19 (45.2) 98 12.13 (1.17) 97 5.64 (0.44)
Donor age .883 .870 .741
$35 years 64 (44.1) 18 (42.9) 82 9.90 (1.09) 81 3.70 (0.45)
<35 years 81 (55.9) 24 (57.1) 105 9.37 (0.98) 102 4.36 (0.37)
Sex match .399 .013 .813
female to male 23 (15.9) 9 (21.4) 32 6.77 (1.26) 31 4.97 (0.73)
other 122 (84.1) 33 (78.6) 155 9.97 (0.83) 152 4.13 (0.31)
Recipient CMV-status .579 .883 .859
negative 57 (43.5) 18 (48.7) 75 9.81 (1.11) 72 4.49 (0.43)
positive 74 (56.5) 19 (51.4) 93 9.47 (1.00) 92 4.27 (0.39)
Donor CMV-status .178 .912 .389
negative 76 (58.0) 26 (70.3) 102 9.55 (0.96) 99 3.55 (0.41)
positive 55 (42.0) 11 (29.7) 66 9.64 (1.17) 65 4.94 (0.36)
ABO match .174 .915 .966
matched 43 (29.7) 8 (19.1) 51 9.37 (1.28) 49 3.70 (0.51)
mismatched 102 (70.3) 34 (81.0) 136 9.76 (0.88) 134 4.53 (0.34)
Diagnosis .309 .001 .014
nonmalignant 27 (18.6) 5 (11.9) 32 15.64 (1.88) 31 5.24 (0.79)
malignant 118 (81.4) 37 (88.1) 155 8.98 (0.77) 152 3.80 (0.29)
Risk status‡ .855 .480 .614
standard 92 (63.5) 26 (61.9) 118 9.84 (0.83) 115 3.94 (0.37)
high risk 53 (36.6) 16 (38.1) 69 9.17 (1.37) 68 4.81 (0.45)
Degree of HLA match .701 .465 .678
10\10 71 (49.0) 23 (54.8) 94 9.18 (0.89) 93 3.75 (0.40)
9\10 50 (34.5) 15 (35.7) 65 9.72 (1.21) 63 4.46 (0.52)
8\10 20 (13.8) 3 (7.1) 23 9.11 (2.80) 23 4.97 (0.67)
7\10 4 (2.8) 1 (2.4) 5 11.27 (6.82) 4 5.71 (1.03)
BFM match status .261 .525 .346
matched ($9/10) 121 (83.5) 38 (90.5) 159 9.47 (0.72) 156 4.02 (0.32)
mismatched (#8/10) 24 (16.6) 4 (9.5) 28 10.19 (2.58) 27 4.97 (0.59)
Stem cell source .000 .000
peripheral blood 145 11.27 (0.84) 143 5.15 (0.30)
bone marrow 42 3.43 (0.39) 40 0.40 (0.29)
Year of transplant .000 .038 .002
2000-2004 43 (62.3) 26 (37.7) 69 7.00 (1.58) 65 2.45 (0.45)
2005-2008 102 (86.4) 16 (13.6) 118 10.06 (0.69) 118 4.94 (0.35)
TBI .317 .014 .103
TBI 37 (72.5) 14 (27.4) 51 8.63 (0.73) 51 3.55 (0.28)
non-TBI 108 (79.4) 28 (20.6) 136 10.57 (0.93) 132 4.72 (0.36)
PB indicates peripheral blood; BM, bone marrow; CMV, cytomegalovirus; ABO, blood group; HLA, human leukocyte antigen; BFM, stem cell transplant
protocol from Berlin-Frankfurt-Mu¨nster group; TBI, total body irradiation; ANC, day of absolute neutrophil count recovery >0.5  109/L; PLT, day of
platelet count recovery >50  109/L.
Univariate analysis was performed by c2-test* and Mann-Whitney U/Kruskal-Wallis test† used for nonparametric variables.
‡Standard risk: ALL/AML in first and second complete remission (CR), CML in first chronic phase, MDS-refractory cytopenia, NHL in CR, any nonma-
lignant disease; high risk: ALL/AML in equal to or greater than third CR or nonremission, CML equal to or greater than accelerated phase, MDS-
refractory anemia with excess of blasts, JMML, NHL in nonremission, any second transplant.
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For statistical comparisons between the 3 studied
cohorts of patients, a chi-square test was used for cat-
egoric parameters, whereas Mann-Whitney U or
Kruskal-Wallis tests were performed for nonparamet-
ric continuous variables. Kaplan-Meier/cumulative in-
cidence methods and log-rank/Gray tests were used
for comparison of time-dependent endpoint outcome
parameters within the studied patient groups described
earlier [20,21]. Variables were analyzed for prognosticimpact on OS, DFS, and the incidence of severe
GVHD (aGVHD grade III-IV and extensive
cGVHD) and included: recipient sex, sexmatch, donor
and recipient age, donor and recipient CMV status,
ABO blood group compatibility, patients’ diagnosis
and risk group, stem cell source (PB versus BM),
infused CD341 and CD31 cell dose per kg, year of
transplant (2000-2004 versus 2005-2008), condition-
ing regimen (TBI versus non-TBI) and degree of
donor-recipient HLA match. Only variables with
1392 Biol Blood Marrow Transplant 16:1388-1401, 2010K. Kałwak et al.a P-value\.2 in univariate analysis were included into
the final multivariate analysis-proportional hazard
(Cox) regression with a backward stepwise approach
[22]. For aGVHD and cGVHD, death without an
event, as well as graft rejection were the competing
risks. Because of a strong correlation between
CD341 and CD31 cell doses, two possible models of
multivariate analysis for OS and DFS are presented.
Furthermore, two possible models of multivariate
analysis for aGVHD grade III-IV are shown, one
including BFM match status (matched versus mis-
matched) and the other including HLA match variant
(graft mismatched at 2 HLA antigens or 3 antigen/al-
leles versus other). For the cell dose variables, the
optimal cut point was determined by taking age-
adjusted medians. Because of a well-known correlation
of CD341 cell doses with age, probabilities of survival
were calculated within groups of patients 0-5 years,
5-10 years, 10-15 years, and 15-20 years old, and
0-10 years and 10-20 years old. The P-values are
2-sided and a significance level of .05 was used as
relevant. Statistical analyses were performed using
Statistica for Windows 8.0 and R-2.10.1 statistical
software package [23].RESULTS
Study Cohorts
One hundred eighty-seven patients were prospec-
tively included in the study: 145 in the PB, and 42 in
the BM groups. The decision about the type of trans-
plant material was made by the donor together with
the local harvest center, and was only in part influenced
by the transplant center’s preference. Patient, donor,
and transplant characteristics were fully comparable
between the 2 cohorts except for the expected higher
infused CD341 and CD31 cell dose in the PB group
and the year of transplant (Table 3). Patients in the
PB group were given statistically significant 3.3 times
more CD341 cells/kg and 12.9 times more (.1 log)
CD31 cells/kg when compared with the BM group
(P\ .001). The cohorts of patients analyzed according
to infused CD341 cell dose/kg were comparable in
terms of patient, donor, and transplant characteristics
except for sex match, diagnosis, year of transplant, the
use of TBI, and, as expected, recipient age and stem
cell source (Table 3). The cohorts of patients analyzed
according to infused CD31 cell dose were comparable
except for diagnosis, year of transplant and, as expected,
recipient age and stem cell source (Table 3). The
cohorts of patients analyzed according to diagnosis
(malignant versus nonmalignant) were comparable
except for, as expected, the age (P\ .05), CD341 and
CD31 cell doses (P\ .05), risk group (P\ .01), and
the use of TBI (P\ .001) (data not shown).Hematologic Recovery
The median day of ANC recovery (.0.5  109/L)
was 14 for PBSC and 18 for BM recipients (P\ .001).
Five patients died without achieving neutrophil recon-
stitution on days 16, 110, 111, 115, and 126 post-
transplant, respectively, because of sepsis in 3 cases
and heart failure or renal insufficiency in the remaining
2 patients. The median day of platelet recovery was 18
for PBSC and 30 for BM recipients (P\ .001). Time to
neutrophil engraftment was significantly shorter in
patients receiving higher doses of both CD341 ($10
 106) and CD31 ($4  108) cells/kg (median day
14 and 16; P\ .001 and P 5 .003, respectively). Sim-
ilarly, platelet recovery in patients who received higher
doses of both CD341 and CD31 cells/kg was achieved
9 and 6 days earlier, respectively (median day 16 and
18 versus 25 and 24; P \ .001 and P 5 .002,
respectively).OS and DFS (Tables 4 and 5)
With a median follow-up of 3.2 years (range: 0.8-
7.6 years, PB group) and 5.4 years (range: 2.3-8.8
years, BM group) there was a statistically significant
advantage in DFS of patients given PBSC versus BM
(0.55 6 0.04 versus 0.4 6 0.08, P \ .05, log-rank,
Figure 1). In terms of OS, there was a trend toward
better OS in the PB group (0.56 6 0.04 versus. 0.43
6 0.08, P 5 0.065, log-rank, Figure 1). As expected,
patients at high risk had a poorer DFS in comparison
with standard risk patients (0.41 6 0.06 versus 0.58
6 0.05, P\ .05). There was no difference in OS and
DFS between patients transplanted from MUDs or
mismatched UDs (including separately 10/10, 9/10,
8/10, allele matched transplants, Table 4) despite the
fact that patients transplanted from mismatched do-
nors were mostly (57.1%) high risk patients according
to BFM criteria, whereas the group of children trans-
planted from matched donors included significantly
fewer high risk individuals (33.3%, P 5 .016, c2-test).
The group of 7/10-allele matched transplanted
children was inconclusive in terms of statistics because
of the low number of patients. Themost striking statis-
tically significant differences in OS and DFS were ob-
served when comparing groups receiving higher and
lower doses of both CD341 and CD31 cells in the
graft. Patients receiving $10  106 and $15.4  106
(.75th percentile) CD341 cells/kg had OS (and
DFS) probability of 0.64 and 0.69 (0.60 and 0.67),
respectively versus 0.44 and 0.47 (0.44 and 0.46)
when given less than the previously mentioned
amounts. Similarly patients given $4  108 and
$6.9  108 (.75th percentile) CD31 cells/kg had
OS (and DFS) probability of 0.61 and 0.71 (0.60 and
0.69), respectively, versus 0.45 and 0.48 (0.43 and
0.46) when infused less than the earlier-mentioned
amounts.
Table 4. Influence of Multiple Variables on Clinical Outcome by Univariate Analysis (Log-Rank* or Gray Test†)
Overall Survival* Disease-Free Survival* aGVHD Grades III-IV† Extensive cGVHD†
Variables N % SE P N % SE P N % SE P N % SE P
Recipient sex .658 .552 .297 .504
male 112 0.51 0.05 112 0.49 0.05 112 0.25 0.04 93 0.16 0.04
female 75 0.56 0.06 75 0.55 0.06 75 0.18 0.05 63 0.20 0.05
Recipient age .028 .050 .085 .755
$10 years 89 0.44 0.06 89 0.43 0.05 89 0.16 0.04 70 0.16 0.05
<10 years 98 0.62 0.05 98 0.59 0.05 98 0.27 0.05 86 0.14 0.04
Donor age .142 .202 .903 .578
$35 years 82 0.49 0.06 82 0.48 0.06 82 0.22 0.05 62 0.13 0.05
<35 years 105 0.56 0.05 105 0.54 0.05 105 0.21 0.04 94 0.16 0.04
Sex match .775 .994 .267 .542
female to male 32 0.45 0.12 32 0.48 0.11 32 0.28 0.08 28 0.11 0.07
other 155 0.54 0.04 155 0.52 0.04 155 0.20 0.03 128 0.16 0.04
Recipient CMV status .796 .742 .896 .391
negative 75 0.55 0.06 75 0.53 0.06 75 0.21 0.05 64 0.18 0.05
positive 93 0.55 0.05 93 0.52 0.05 93 0.22 0.04 80 0.13 0.04
Donor CMV status .541 .486 .107 .780
negative 102 0.54 0.05 102 0.51 0.05 102 0.25 0.04 86 0.15 0.04
positive 66 0.56 0.07 66 0.55 0.07 66 0.15 0.05 58 0.14 0.05
ABO match .774 .965 .260 .201
matched 51 0.50 0.07 51 0.50 0.07 51 0.27 0.06 44 0.21 0.07
mismatched 136 0.54 0.05 136 0.52 0.04 136 0.19 0.04 112 0.13 0.04
Diagnosis .273 .165 .172 .240
nonmalignant 32 0.66 0.08 32 0.66 0.08 32 0.12 0.06 27 0.08 0.06
malignant 155 0.50 0.04 155 0.48 0.04 155 0.23 0.03 129 0.16 0.04
Risk group‡ .082 .046 .575 .820
standard 118 0.59 0.05 118 0.58 0.05 118 0.20 0.04 99 0.15 0.04
high risk 69 0.43 0.06 69 0.41 0.06 69 0.23 0.05 57 0.14 0.05
Year of transplant .184 .214 .425 .372
2000-2004 69 0.50 0.06 69 0.46 0.06 69 0.25 0.05 55 0.18 0.06
2005-2008 118 0.60 0.05 118 0.54 0.05 118 0.19 0.04 101 0.13 0.04
TBI .858 .850 .330 .461
TBI 51 0.50 0.04 51 0.51 0.04 51 0.25 0.06 44 0.11 0.03
non-TBI 136 0.50 0.04 136 0.52 0.04 136 0.20 0.04 112 0.16 0.04
Degree of HLA-match .628 .228 .055 .720
10\10 94 0.54 0.06 94 0.55 0.05 94 0.16 0.04 78 0.22 0.04
9\10 65 0.51 0.06 65 0.48 0.06 65 0.23 0.05 56 0.16 0.05
8\10 23 0.56 0.10 23 0.52 0.10 23 0.30 0.10 19 0.22 0.11
7\10 5 0.40 0.22 5 0.20 0.18 5 0.60 0.22 3 no ext cGVHD
BFM HLA-match status .692 .334 .039 .645
matched ($9/10) 159 0.53 0.04 159 0.52 0.04 159 0.19 0.03 134 0.14 0.03
mismatched (#8/10) 28 0.53 0.10 28 0.46 0.09 28 0.36 0.09 22 0.19 0.10
HLA-match variants .189 .024 .008 .439
8/10ant + 7/10 12 0.42 0.14 12 0.25 0.13 12 0.50 0.15 8 0.25 0.20
other 175 0.54 0.04 175 0.53 0.04 175 0.19 0.03 148 0.14 0.03
(Continued )
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Table 4. (Continued )
Overall Survival* Disease-Free Survival* aGVHD Grades III-IV† Extensive cGVHD†
Variables N % SE P N % SE P N % SE P N % SE P
Stem cell source .065 .047 .922 .275
peripheral blood 145 0.56 0.04 145 0.55 0.04 145 0.21 0.04 127 0.14 0.04
bone marrow 42 0.43 0.08 42 0.40 0.08 42 0.21 0.07 29 0.21 0.08
Infused CD34+ cell dose .009 .018 .889 .780
$10  106/kg 86 0.64 0.05 86 0.60 0.05 86 0.22 0.05 77 0.14 0.05
<10  106/kg 101 0.44 0.05 101 0.44 0.05 101 0.21 0.04 79 0.15 0.05
CD34+ dose per kg .030 .038 0.93 .842
Q1 47 0.41 0.07 47 0.41 0.07 47 0.19 0.06 34 0.18 0.07
Q2 47 0.43 0.08 47 0.43 0.08 47 0.23 0.06 39 0.13 0.06
Q3 47 0.59 0.08 47 0.55 0.08 47 0.23 0.06 41 0.18 0.07
Q4 46 0.69 0.07 46 0.67 0.07 47 0.20 0.06 42 0.12 0.05
Infused CD3+ cell dose .016 .012 .609 .981
$4  108/kg 96 0.61 0.06 96 0.60 0.05 96 0.20 0.04 83 0.15 0.04
<4  108/kg 87 0.45 0.05 87 0.43 0.05 87 0.23 0.05 71 0.14 0.05
CD3+ dose per kg .062 .035 .888 .632
Q1 46 0.41 0.07 46 0.39 0.07 46 0.22 0.06 34 0.12 0.07
Q2 46 0.52 0.08 46 0.49 0.08 46 0.22 0.06 41 0.15 0.06
Q3 46 0.50 0.09 46 0.49 0.09 46 0.17 0.06 40 0.20 0.07
Q4 45 0.71 0.07 45 0.68 0.07 45 0.24 0.06 39 0.10 0.05
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host-disease; HLA, human leukocyte antigen; TBI, total body irradiation; BFM, stem cell transplant protocol from Berlin-Frankfurt-
Mu¨nster group; 8/10 ant, two HLA-antigen mismatch; ext, extensive; Q, quartiles of CD34+ dose per kg: Q1 <5.33, Q2 5.33-9.72, Q3 9.73-15.42, Q4 >15.42; quartiles of CD3+ dose per kg: Q1 <1.71, Q2 1.71-
4.26, Q3 4.27-6.85, Q4 >6.85.
‡Standard risk: ALL/AML in first and second complete remission, CML in first chronic phase, MDS-refractory cytopenia, NHL in complete remission, any nonmalignant disease; high risk: ALL/AML in equal to or greater
than third complete remission or nonremission, CML equal to or greater than accelerated phase, MDS-refractory anemia with excess of blasts, JMML, NHL in nonremission, any second transplant.
*Log-rank test.
†Gray test.
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Table 5. Survival Analyses in Age Groups According to Age-Adjusted Medians of Infused CD34+ and CD3+ Cell Doses per kg (Log-
Rank)
Infused CD34+ Cell Dose/kg Infused CD3+ Cell Dose/kg
<Me for Age Group $Me for Age Group
P
< Me for Age Group $Me for Age Group
PSurvival Age Group N % SE N % SE N % SE N % SE
OS 0-5 23 0.47 0.11 24 0.83 0.08 .006 23 0.61 0.10 23 0.74 0.09 .364
5-10 26 0.50 0.11 25 0.62 0.10 .560 26 0.55 0.10 25 0.56 0.11 .965
10-15 25 0.46 0.10 25 0.59 0.10 .421 25 0.43 0.10 24 0.59 0.11 .290
15-20 20 0.15 0.08 19 0.58 0.13 .001 19 0.31 0.11 18 0.44 0.14 .225
DFS 0-5 23 0.38 0.10 24 0.83 0.08 .001 23 0.52 0.10 23 0.74 0.09 .150
5-10 26 0.52 0.10 25 0.58 0.10 .703 26 0.56 0.10 25 0.54 0.10 .774
10-15 25 0.46 0.10 25 0.59 0.10 .435 25 0.43 0.10 24 0.60 0.11 .276
15-20 20 0.15 0.08 19 0.54 0.13 .002 19 0.31 0.11 18 0.40 0.13 .344
aGvHD grade III-IV 0-5 23 0.31 0.10 24 0.21 0.08 .359 19 0.06 0.05 21 0.10 0.07 .898
5-10 25 0.36 0.10 24 0.22 0.09 .218 25 0.33 0.10 20 0.11 0.07 .303
10-15 24 0.13 0.07 25 0.12 0.06 .944 22 0.14 0.07 21 0.16 0.09 .391
15-20 19 0.32 0.11 18 0.12 0.08 .093 12 0.36 0.15 14 0.16 0.10 .669
ext cGvHD 0-5 17 0.07 0.06 24 0.13 0.07 .538 19 0.06 0.05 21 0.10 0.07 .618
5-10 24 0.29 0.09 21 0.15 0.08 .236 25 0.33 0.10 20 0.11 0.07 .076
10-15 21 0.20 0.09 23 0.11 0.08 .297 22 0.14 0.07 21 0.16 0.09 .964
15-20 10 0.33 0.16 16 0.20 0.10 .308 12 0.36 0.15 14 0.16 0.10 .258
Me indicates median for age groups (CD34+ cell dose: 0-5 years, 16.02 106; 5-10 years, 11.68 106; 10-15 years, 8.77 106; 15-20 years, 6.41 106;
CD3+ cell dose: 0-5 years, 6.96 108; 5-10 years, 5.15 108; 10-15 years, 3.60 108; 15-20 years, 2.14 108); OS, overall survival; DFS, disease-free
survival; aGVHD, acute graft-versus-host disease; ext cGVHD, extensive chronic graft-versus-host disease.
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CD31 doses using quartiles revealed the best OS and
DFS rates in the fourth quartile and the worst in the
first one. Furthermore, we analyzed the impact of
CD341 and CD31 cell doses (higher and lower than
age-adjusted medians) on OS and DFS in smaller age
cohorts, showing the survival advantage when using
higher doses of CD341 cells/kg (Table 5 and
Figure 2). In age groups 0-10 years and 10-20 years
old, the survival advantage of patients who received
higher doses of CD341 (Figure 2) and CD31 cells
(data not shown) was clearly statistically significant.
These clinically important results were confirmed
in a multivariate analysis showing that both infused
CD341 and CD31 cell doses lower than 10  106/kgFigure 1. Probability of OS and DFS according to stem cell source. DFS
and OS are depicted for the PB group (upper lines) and BM group (lower
lines). N, number of patients in each arm of the study cohort, P (log-
rank).and 4  108/kg, respectively, were significant, inde-
pendent risk factors for mortality (relative risk, RR
1.8, 95% confidence interval [CI] 1.2-2.8, P 5 .009,
and RR 1.7, CI 1.1-2.7, respectively; Table 6 and
Figure 3A). Regarding DFS, the multivariate analysis
has revealed another independent risk factor for poor
outcome apart from the 2 just-mentioned grafted cell
doses, which was the use of donors mismatched at
2 HLA antigens or 3 HLA allele/antigens (Table 6
and Figure 3B).
With a median follow-up of 3.5 years (range:
0.8-8.8 years), 103 patients (55.1%) remain alive.
Eighty-four patients died because of relapse or early/Figure 2. Probability of OS according to infused age-adjusted median
dose of CD341 cells/kg. Dotted and short-dashed lines depict patients
younger than 10 years given CD341 cell dose below and above age-
adjusted median (12.13  106 CD341 cells/kg), whereas dashed and
solid lines depict patients older than 10 years given CD341 cell dose
above and below age-adjusted median (7.2  106 cells/kg). N, number
of patients in each arm of the study cohort, P (log-rank).
Table 6. Multivariate Analysis of Risk Factors for Overall-, Disease-Free Survival, and the Incidence of aGVHD Grades III-IV
Clinical
Outcome Variable*
Relative
Risk 95% CI
P
(Partial)
P
(Model)
Overall survival I CD34+ cell dose (<10  106/kg) 1.80 1.15 2.81 .010 .009
or
II CD3+ cell dose (<4  108/kg) 1.71 1.10 2.67 .017 .016
Disease-free survival I 8/10ant + 7/10 2.54 1.27 5.08 .008 .004
CD34+ cell dose (<10  106/kg) 1.68 1.09 2.59 .019
or
II 8/10ant + 7/10 2.44 1.18 5.07 .017 .005
CD3+ cell dose (<4  108/kg) 1.76 1.14 2.71 .010
Incidence of acute GVHD
grades III-IV
I BFM match status (8/10 + 7/10) 2.19 1.07 4.48 .032 .046
or
II 8/10ant + 7/10 3.72 1.56 8.90 .003 .011
CI indicates confidence interval; GVHD, graft-versus-host disease
*Variables analyzed for prognostic impact on survival and incidence of aGVHD grade III-IV: recipient sex, sex match, donor and recipient age, donor and
recipient cytomegalovirus status, ABO blood group compatibility match, patients’ diagnosis and risk group, stem cell source (peripheral blood versus
bone marrow), infused CD34+ and CD3+ cell dose per kg, donor-recipient HLA matching: degree of HLA-match or BFM match status (matched versus
mismatched) or 8/10 ant (2 antigen mismatch) + 7/10 versus other. Only variables with a P-value < .2 in univariate analysis (log-rank test) were included in
the final multivariate analysis: proportional hazard (Cox) regression with a backward stepwise approach.
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day 1100 was 16.0% and overall TRM reached
31.0%. The reasons for death were: relapse n 5 21
(11.2%), secondary malignancies n 5 2 (1.1%), sepsis
n 5 14 (7.5%), other infection (viral) n 5 7 (3.7%),
aGVHD n 5 12 (6.4%), cGVHD n 5 9 (4.8%),
thrombotic thrombocytopenic purpura (TTP) n 5 6
(3.2%), invasive fungal infection n5 3 (1.6%), pulmo-
nary embolism n 5 3 (1.6%), veno-occlusive liver dis-
ease n 5 2 (1.1%), brain infarct n 5 2 (1.1%), aorta
thrombosis n 5 1 (0.5%), heart failure n 5 1 (0.5%)
and renal insufficiency n 5 1 (0.5%). There were no
statistically significant differences in the TRM causes
between the studied patients’ cohorts. Year of trans-
plant (2000-2004 versus 2005-2008) influenced nei-
ther OS, DFS, or the incidence of severe GVHD.
Severe aGVHD Grade III-IV (Table 4)
An analysis of the incidence of moderate-to-severe
aGVHD grade II-IV (59.9%) was not the aim of this
study, because moderate aGVHD grade II no longer
seems to be a problem in treatment when compared
with severe aGVHD grade III-IV. In a recently pub-
lished large pediatric study, there was absolutely no
difference in TRM between children developing
aGVHD grade II and those with none or grade I
aGVHD [24].
The cumulative incidence of clinically important
severe aGVHD grade III-IV was comparable between
the recipients of PB versus BM (Figure 4A). As shown
in Tables 4 and 5, infused CD341 or CD31 cell dose
had absolutely no impact on the occurrence of severe
aGVHD (Figure 4B and C). As expected, the more
HLA mismatches were in the donor-recipient pairs,
the more frequent the cumulative incidence of severe
aGVHD was (Figure 5A). There was a significantly
higher incidence of severe aGVHD in the mismatched
group (0.36 6 0.09) versus matched group (0.19 6
0.03,P5 .039, log-rank)whenusingALL internationalBFM SCT 2008 study criteria. However, this did not
adversely affect OS or DFS, as shown previously
(Table 4). Within the mismatched group the highest
risk of severe aGVHD was associated with the use of
donor-recipient pairs mismatched at 2 HLA antigens
(not 2 alleles or 1 antigen 1 1 allele) and 3 HLA
allele/antigens (Figure 5B). These clinically relevant
results were confirmed in a multivariate analysis show-
ing that either the use of mismatched donors according
to BFM criteria (RR 2.2, 95% CI 1.1-4.5, P 5 .046,
Table 6) or, in another model, the use of donors mis-
matched at 2 HLA antigens or 3 HLA allele/antigens
(RR 3.7, 95% CI 1.6-8.9, P 5 .011) were significant,
independent risk factors for incidence of severe
aGVHD.
cGVHD (Table 4)
The cumulative incidence of clinically relevant ex-
tensive cGVHD was comparable between the recipi-
ents of PB and BM (0.14 6 0.04 for PB versus 0.21 6
0.08 for BM groups, Figure 6A). As shown in Tables
4 and 5, infused CD341 or CD31 cell dose had no
impact on the occurrence of extensive cGVHD
(Figure 6B and C). There was a visible trend toward
a higher cumulative incidence of extensive cGVHD
in patients whose donors were mismatched at 2 HLA
antigens (not 2 alleles or 1 antigen 1 1 allele) and 3
HLA allele/antigens (P 5 .074). However, the multi-
variate analysis disclosed no significant risk factors for
the development of extensive cGVHD.DISCUSSION
There is a worldwide concern whether to limit the
dose of infused CD341 and CD31 cells/kg in recipi-
ents of both related and unrelated donor grafts. It is
well recognized that doses of different cellular subsets
within grafts can affect the clinical outcome following
Figure 3. Independent risk factors associated with probability of OS
and DFS. (A) Dashed line depicts lower OS in patients grafted with
\10  106 CD341 cells/kg, whereas solid line shows better survival
in children who are free from the above-mentioned independent risk
factor. (B) Dashed line depicts lower probability of DFS in patients
with both independent risk factors: CD341 cell dose per kg\10 
106 and the graft mismatched at 2 HLA antigens or 3 antigen/alleles,
whereas solid line presents patients without the above-mentioned risk
factors. RR, relative risk, CI, confidence interval, P (hazard Cox regres-
sion model).
Figure 4. Incidence of severe aGVHD grade III-IV. (A) Comparison be-
tween PB (solid line) and BM recipients (dotted line). (B) Comparison
between patients grafted with Q1 (solid line), Q2 (short-dashed line),
Q3 (dotted line), and Q4 (long-dashed line); Q, quartile dose of
CD341 cells/kg. (C) Comparison between patients grafted with Q1
(solid line), Q2 (short-dashed line), Q3 (dotted line), and Q4 (long-
dashed line); Q, quartile dose of CD31 cells/kg. N, number of patients
in each group of patients; quartiles of CD341 dose per kg  106: Q1
\5.33, Q2 5.33-9.72, Q3 9.73-15.42, Q4 .15.42; quartiles of CD31
dose per kg  108: Q1 \1.71, Q2 1.71-4.26, Q3 4.27-6.85,
Q4 .6.85, P (log-rank, cumulative incidence).
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association between higher CD341 cell dose and
improved survival after HLA-identical BMT has
been reported [25]. The impact of higher CD341
(and presumably CD31) cell dose in the graft on the
risk of cGVHD is controversial [26], as some studies
have reported only distinct correlations [27] or none
at all [16,28].
There are only a few studies analyzing the impact
of cell dose in the graft on the outcome ofUDPBSCT.
In a large single-center study Nakamura et al. [13]
showed a correlation between higher CD341 cell
doses and faster lymphocyte recovery leading to
a decrease in relapse rate. A recently published large
multicenter prospective study clearly showed that
NMDP-facilitated UD PBSCTs [16] result in rapid
engraftment and survival comparable to previous stud-
ies onUDBMT [29]. The key finding of that study wasthe independent predictive value of the higher CD341
cell dose for significant improvement in patients’ out-
come including faster hematologic recovery and better
OS [16]. CD341 cell doses between 4.5 and 9.5 106/kg
Figure 5. Incidence of severe aGVHD grade III-IV, N, number of pa-
tients in each arm of the study cohort. (A) Incidence of severe aGVHD
according to degree of HLA match, 10/10, full allele match; 9/10, single
HLA allele/antigen mismatch; 8/10, 2 HLA allele/antigen mismatches; 7/
10, three HLA allele/antigen mismatches. (B) Incidence of severe
aGVHD in patients transplanted from donors mismatched (dotted
line) at 2 HLA antigens (8/10 ant) or 3 HLA allele/antigens (7/10) versus
others, P (log-rank).
Figure 6. Incidence of extensive cGVHD, N, number of patients in
each arm of the study cohort. (A) Comparison between PB (solid
line) and BM recipients (dotted line). (B) Comparison between patients
grafted with $10  106 CD341 cells/kg (solid line) and\10  106
CD341 cells/kg (dotted line). (C) Comparison between patients grafted
with $4  108 CD31 cells/kg (solid line) and\4  108 CD31 cells/kg
(dotted line), P (log-rank).
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improvement in 3-year OS in recipients of MA condi-
tioning [16]. Doses greater than 9.5  106/kg did not
further improve OS in the earlier mentioned study
[16], which stands in contrast to our data, showing
best OS and DFS in patients receiving CD341 cell
doses above the 75th percentile ($15.4  106/kg),
but it should be noted that the highest CD341 cell
doses in our study were given mostly to younger
patients. These patients generally have better progno-
sis, but there were still a few high-risk patients in the
youngest cohort including children after previous
unsuccessful haploidentical transplants. Another
confirmation of our results may be found in the most
recently published study by Collins et al. [17], showing
higher survival rates in patients grafted with PBSCs
fromUD containing.5 106 CD341 cells/kg. There
is, however, one important point that cannot be
missed: all previously cited studies included patients
who were not given in vivo T cell depletion asGVHD prophylaxis. On the contrary, our study is
based on patients who received rabbit ATG or CAM-
PATH. The dose of rabbit ATGwe used was not high:
the majority of our patients were given ATG-
Fresenius at a dose of 30 mg/kg, which is lower than
the dose recommended by BFM group (60 mg/kg)
or Sedlacek et al. [2,3] (40 mg/kg). Another point is
Biol Blood Marrow Transplant 16:1388-1401, 2010 1399Effect of CD341 or CD31 Dose on Pediatric UD-HSCTthe use of rabbit ATG (Thymoglobuline). Here,
the recommended dose is around 7.5 mg/kg, and our
dosage of Thymoglobuline in those few patients was
similar or slightly higher (10 mg/kg). The majority
of children, however, were given the standard (rather
low) dose of ATG-Fresenius (30 mg/kg).
In our study, we demonstrated a higher survival
rate among the patients who had received higher
doses: the more CD341 cells were given, the better
survival rates were achieved. Of course, the just-
mentioned result is slightly biased by the fact that
younger children with more chances to receive higher
dose of CD341 cells/kg usually had a better outcome.
To avoid this possible bias, we analyzed the age groups
0-10 years and 10-20 years, and 0-5years, 5-10 years,
10-15 years, and older separately, looking at the im-
pact of high and low doses in different age cohorts.
Our age-matched analysis (Table 5) proved that the
megadose concept was working within almost all age
cohorts in terms of survival. Because of a lower number
of cases, in age groups 5-10 years and 10-15 years, the
survival advantage was not statistically significant, yet
visible. When looking at the larger age groups of
0-10 years and 10-20 years old, the survival advantage
of patients who received higher doses was clearly sta-
tistically significant (Figure 2). We analyzed lower
dose cutoffs to find a cell amount that is more achiev-
able for adolescents and adults by looking at the me-
dian values for different age groups (Table 5 and
Figure 2). For the age group of 0-10 years, the dose
over 12  106 CD341 cells/kg favored outcome,
whereas in older children .10 years old the dose .7
 106 CD34/kg promoted survival. Those cell doses
are achievable in pediatric patients when PBSC is
used. The dose of 5  106 CD341/kg obtainable in
adult studies [16,17] might be equivocal to the dose
of 10  106 CD34/kg in children. In conclusion, we
think that the easily achievable dose of 10-12  106
CD34/kg for children\10 years or 7  106 for older
children may be desired in pediatric patients
undergoing unrelated donor PBSCT (provided that
in vivo T cell depletion is used). Multicenter
randomized studies are required, however, to further
prove this concept.
One may ask whether the year of transplant or di-
agnosis influenced our results. Indeed, more BM than
PBSC transplants were performed in the years
2000-2004 (Table 3); however, there was absolutely
no difference in outcomes between the studied periods
(Table 4). The major reason for this might be a well-
standardized ‘‘high-resolution’’ HLA typing used in
our center since the beginning and a uniform use of
in vivo T cell depletion.
Despite some differences between patients with
nonmalignant and malignant disorders, the majority
of variables in both groups were comparable and those
2 groups canbe included together. In the nonmalignantgroup, we had both older patients at risk of transplant-
related complications (children with SAA, Fanconi
anemia, or metabolic disorders) and some very
young patients (severe combined immunodeficiency
[SCID]), who had their second transplants after previ-
ous early haploidentical graft rejection or late graft
failure. Patients with nonmalignant diseases tended to
be younger, but had the same HLA matching levels
accepted, the same GVHD prophylaxis and the same
use of BM versus PBSC.
The major concern when using higher doses of
CD341 and CD31 cells is the increased risk of
GVHD. We have found absolutely no correlation
between the CD341 and CD31 cell dose and the inci-
dence of severe aGVHD and cGVHD, which remains
in line with the NMDP studies [16,17]. In an adult
study on UD HSCT using reduced-intensity condi-
tioning (RIC) patients receiving a CD341 cell dose
$17  106 per kg had a higher incidence of GVHD
[14]. In our study, such a high dose of grafted
CD341 cells ($15.4  106/kg, ie, .75th percentile)
promoted a significantly better OS and DFS, and did
not influence GVHD. The majority of our patients
(except for patients with SAA or Fanconi anemia)
were conditioned, however, with an MA regimen,
which may make an important difference and they
were children, not adults (median age in Remberger
et al. [14] study was 50 years). It was not the first
time that PBSC appeared to have similar cGVHDout-
comes to BM in children: Meisel et al. [12] showed
comparable risk of both aGVHD and cGVHD in
a small pediatric cohort of PBSC and BM recipients.
Most patients in that study received ATG/ALG sero-
therapy as GVHD prophylaxis. All children in our
study received ATG or CAMPATH as GVHD pro-
phylaxis, and beside the well-known lower risk for
GVHD in children it appeared to be the major factor
for comparable rates of cGVHD among PBSC and
BM recipients.
To the best of our knowledge, there are virtually
no studies on the effect of cell dose on the outcome
in pediatric patients undergoing UD HSCT. Further-
more, little is known about the impact of CD31 cell
dose on OS, DFS, and the incidence of GVHD even
in adult UD transplant patients.
In our opinion, the use of ATG is the most impor-
tant factor enabling successful use of UD PBSCT in
children. The results of our study, showing improved
OS and DFS and no difference in severe GVHD in pa-
tients receiving higher CD341 and CD31 cell doses,
make PBSC transplants with high CD341 and CD31
cell doses a feasible and perhaps desirable option.
The dose above our 25th percentile, that is, 5  106
CD34/kg may be easily achieved for any children
when using PBSC. Even in an adult study of Re-
mberger et al. [14] median CD341 cell dose in UD
PBSC was 7.5  106/kg. Our study results remain in
1400 Biol Blood Marrow Transplant 16:1388-1401, 2010K. Kałwak et al.line with 2 very recent NMDP papers, confirming the
beneficial effects of higher CD341 cell dose in unre-
lated donor transplants in prevalent adult populations
[16,17]. Our data comes from a pediatric cohort of
patients and cannot be easily compared with adult
data, but the message remains the same. It is
important to note that PBSCs containing 1 log more
T cells and higher amounts of CD341 cells are not
worse (if not better) for the outcome. Furthermore,
there seems to be no need to drastically limit the
infused dose of CD341 or CD31 cells/kg in case
a transplant center is given high amounts of CD341
cells from an unrelated good mobilizer.
HLA disparity is one of the most important factors
governing the severity of both aGVHD and cGVHD
[29,30]. An important finding of our study is the
similar outcome of transplants using HLA allele
mismatched (7-8/10) and matched (9-10/10) UDs
(according to BFM criteria). Our concluding remarks
reflect the results of the Sedlacek study [2,3]. The
use of in vivo T cell depletion is certainly
a prerequisite in GVHD prophylaxis, as shown by
Sedlacek et al. [2].
In summary, we have demonstrated for the first
time in a large pediatric cohort that higher doses of
transplanted CD341 and CD31 cells lead to improved
survival without an increased risk of severe aGVHD or
cGVHD. The study findings may be limited to the
population of patients receiving in vivo T cell deple-
tion, which is now broadly used in unrelated donor set-
tings in Europe. With regard to the degree of HLA
match, it seems that transplants from 8 of 10 allele
matched donors (with maximum 1 mismatched anti-
gen) do not influence OS, whereas one should avoid
performing transplants from 2 HLA-antigens or
3 allele/antigen mismatched donors.ACKNOWLEDGMENTS
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